Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine.

Molecular oncology - 1 Dec 2025

Concetti Livia, Scimeca Manuel, Bischof Julia, Woodsmith Jonathan, Agostini Massimiliano, Fiorani Cristina, Shi Yufang, Candi Eleonora, Melino Gerry, Mauriello Alessandro, Sica Giuseppe S

Abstract excerpt

Colorectal cancer (CRC) is a heterogenous disease with distinct biological and clinical subgroups, each with different prognoses and responses to therapy. In this case report, taking inspiration from a case of locally advanced CRC with serine/threonine-protein kinase B-raf (BRAF) V600E mutation, we highlight an atypical consensus molecular subtype 1 (CMS1). Deep multi-omic analyses showed a limited expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to BRAF gene

Share to Immunity

Share to Multiomics

Share to Mutation

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 40878818
DOI: 10.1002/1878-0261.70023
PMCID: PMC12688173

Genes

WEE1
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicinePMID 40878818Read ↗

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.Semantic proximity Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

Colorectal Cancers: An Update on Their Molecular PathologySemantic proximity Read ↗

Investigation of colorectal cancer in accordance with consensus molecular subtype classificationSemantic proximity Read ↗

Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approachSemantic proximity Read ↗

The consensus molecular subtypes of colorectal cancer.Semantic proximity Read ↗

Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.Semantic proximity Read ↗

Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancerSemantic proximity Read ↗

Molecular landscape and sub-classification of gastrointestinal cancers: a review of literatureSemantic proximity Read ↗

Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancerSemantic proximity Read ↗

Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancerSemantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.